NCT02591615 - Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

January 4, 2019

Study Completion Date

July 4, 2020

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

MK-3475

Dose frequency of Q3W, Day 1 of each cycle

DRUG

Carboplatin

Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)

DRUG

Paclitaxel

Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)

DRUG

Pemetrexed

Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)

Trial Locations (11)

13210

SUNY Upstate Medical University, Syracuse

43210

The Ohio State University, Columbus

50309

Medical Oncology & Hematology Associates, Des Moines

55416

Metro MN Community Oncology Research Consortium, Minneapolis

60201

NorthShore University HealthSystem, Evanston

60637

The University of Chicago Medical Center, Chicago

73104

University of Oklahoma Health Sciences Center Stephenson Cancer Center, Oklahoma City

92093

UCSD Moores Cancer Center, La Jolla

04412

EMMC Cancer Care, Brewer

03301

NH Oncology (Concord), Concord

03756

Dartmouth Hitchcock Medical Center, Lebanon

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Alliance Foundation Trials, LLC.

OTHER